Table 2.
Demographics and sample descriptives (n = 717).
| Total %(n) | Non-Hispanic Black± | Non-Hispanic White± | Known BRCA mutation¥ | No known BRCA mutation¥ | |
|---|---|---|---|---|---|
| HCP-related Facilitators |
|||||
| PPR with PCP/WHP > 5 yearsю | 47.1 % (334) | 40.6 % (99) | 50.5 % (235) | 54.9 % (78) | 45.1 % (256) |
| Risk Discussion with PCP/WHP∞ | 81.7 % (581) | 78 % (192) | 83.7 % (389) | 99.3 % (142) | 77.3 % (439) |
| Seen Specialistα | 46.4 % (332) | 33.2 % (83) | 53.4 % (249) | 89.7 % (131) | 35.3 % (201) |
| Screening Concordanceμ | |||||
| Clinical Breast Exam | 67.7 % (462) | 59.9 % (145) | 72.0 % (317) | 93.4 % (127) | 61.4 % (335) |
| Mammography | 72.3 % (295) | 58.2 % (78) | 79.2 % (217) | 90.8 % (108) | 64.7 % (187) |
| Breast MRI | 34.1 % (159) | 17.0 % (26) | 42.5 % (133) | 76.1 % (108) | 15.7 % (51) |
| Awareness of Preventive Options+ | |||||
| Preventive Mastectomy | 84.1 % (601) | 75.5 % (188) | 88.6 % (413) | 86.3 % (126) | 83.5 % (475) |
| Preventive Oophorectomy | 62.2 % (440) | 47.2 % (116) | 70.1 % (324) | 89.7 % (130) | 55.1 % (310) |
| Chemoprevention | 39.3 % (278) | 25.0 % (62) | 47.1 % (216) | 78.1 % (114) | 29.2 % (164) |
| Race± | |||||
| Non-Hispanic Black | 35.0 % (251) | n/a | n/a | 18.5 % (27) | 39.2 % (224) |
| Non-Hispanic white | 65.0 % (466) | n/a | n/a | 81.5 % (119) | 60.1 % (347) |
| BRCA Status¥ | |||||
| Known BRCA Mutation | 20.4 % (146) | 10.8 % (27) | 25.5 % (119) | n/a | n/a |
| No Known BRCA Mutation | 79.6 % (571) | 89.2 % (224) | 74.5 % (347) | n/a | n/a |
Participants indicated how long their longest relationship was with a PCP/WHP; 0 = “≤ 5 years”, 1 = “> 5 years”.
Participants indicated whether they had ever discussed BC risk with a PCP/WHP; 0 = ”Never”, 1 = ”A little” or “A lot”.
Participants indicated whether they had ever seen a specialist about their BC risk; 0 = ”Never”, 1 = ”At least once”.
Participants who were recommended a given screening modality by NCCN guidelines according to their personalized risk score indicated whether they had undergone a given screening modality in the last year; 0 = ”No”, 1 = ”Yes”.
Participants were given definitions of risk-reduction options high-risk women are recommended to be aware of by the NCCN and indicated whether they had ever heard of the option; 0 = ”No”, 1 = ”Yes”.
Participants indicated whether they were non-Hispanic Black or non-Hispanic white= ; 0 = ”Non-Hispanic white”, 1 = ”Non-Hispanic Black”.
Participants indicated whether they had ever received genetic testing and learned they had a BRCA mutation; 0 = ”No”, 1 = ”Yes”.